JP2009539367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539367A5 JP2009539367A5 JP2009513764A JP2009513764A JP2009539367A5 JP 2009539367 A5 JP2009539367 A5 JP 2009539367A5 JP 2009513764 A JP2009513764 A JP 2009513764A JP 2009513764 A JP2009513764 A JP 2009513764A JP 2009539367 A5 JP2009539367 A5 JP 2009539367A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fkbp
- seq
- fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 239000012634 fragment Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940124443 chemopreventive agent Drugs 0.000 claims 2
- 239000012627 chemopreventive agent Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 229960005310 aldesleukin Drugs 0.000 claims 1
- 108700025316 aldesleukin Proteins 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000009120 supportive therapy Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0611405.2 | 2006-06-09 | ||
| GBGB0611405.2A GB0611405D0 (en) | 2006-06-09 | 2006-06-09 | FKBP-L: A novel inhibitor of angiogenesis |
| PCT/GB2007/002107 WO2007141533A2 (en) | 2006-06-09 | 2007-06-08 | Fkbp-l and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539367A JP2009539367A (ja) | 2009-11-19 |
| JP2009539367A5 true JP2009539367A5 (enExample) | 2010-07-29 |
| JP5474535B2 JP5474535B2 (ja) | 2014-04-16 |
Family
ID=36745574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513764A Expired - Fee Related JP5474535B2 (ja) | 2006-06-09 | 2007-06-08 | Ｆｋｂｐ−ｌおよびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9381228B2 (enExample) |
| EP (1) | EP2040728B1 (enExample) |
| JP (1) | JP5474535B2 (enExample) |
| CN (1) | CN101489575B (enExample) |
| AU (1) | AU2007255196B2 (enExample) |
| CA (1) | CA2657947C (enExample) |
| CY (1) | CY1116970T1 (enExample) |
| DK (1) | DK2040728T3 (enExample) |
| ES (1) | ES2548332T3 (enExample) |
| GB (1) | GB0611405D0 (enExample) |
| HU (1) | HUE028099T2 (enExample) |
| IL (1) | IL195580A (enExample) |
| NZ (2) | NZ600690A (enExample) |
| PL (1) | PL2040728T3 (enExample) |
| PT (1) | PT2040728E (enExample) |
| SI (1) | SI2040728T1 (enExample) |
| WO (1) | WO2007141533A2 (enExample) |
| ZA (1) | ZA200810323B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| PT2332968T (pt) | 2003-11-05 | 2016-08-17 | Harvard College | Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| EP2118123B1 (en) | 2007-01-31 | 2015-10-14 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP3159352B1 (en) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Stitched polypeptides |
| GB0724393D0 (en) * | 2007-12-14 | 2008-01-23 | Univ Ulster | Use of FKBPL gene to identify a cause of infertility |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| CN102203126A (zh) | 2008-09-22 | 2011-09-28 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| GB0908589D0 (en) * | 2009-05-19 | 2009-06-24 | Univ Belfast | Assay method |
| WO2011008260A2 (en) * | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| AU2010298338A1 (en) | 2009-09-22 | 2012-04-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
| WO2012174423A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of rab gtpase function |
| WO2013052803A2 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| EP2920197B1 (en) | 2012-09-26 | 2021-03-17 | President and Fellows of Harvard College | Proline-locked stapled peptides and uses thereof |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| EP2991665A4 (en) | 2013-03-13 | 2016-11-09 | Harvard College | STACKED AND GRAFTED POLYPEPTIDES AND USES THEREOF |
| KR20160019547A (ko) | 2013-06-14 | 2016-02-19 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 안정화된 폴리펩티드 인슐린 수용체 조절제 |
| CN111620940A (zh) | 2014-05-21 | 2020-09-04 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| MX389354B (es) | 2014-09-24 | 2025-03-20 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
| KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| EP3402480B1 (en) | 2016-01-11 | 2021-03-24 | EpicentRx, Inc. | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| WO2017136312A1 (en) | 2016-02-02 | 2017-08-10 | Splash Pharmaceuticals, Inc. | Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer |
| CN109475598A (zh) * | 2016-06-22 | 2019-03-15 | 阿尔麦克探索有限公司 | 眼部疾病的治疗 |
| MX2019004280A (es) | 2016-10-14 | 2019-09-18 | Epicentrx Inc | Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina. |
| EP3528831B1 (en) * | 2016-10-19 | 2022-09-21 | Royal College of Surgeons in Ireland | Use of fkbp-l polypeptides and nucleic acids for the treatment of obesity |
| CN108362870A (zh) * | 2017-01-27 | 2018-08-03 | 武汉三鹰生物技术有限公司 | 一种用于人fkbpl蛋白的酶联免疫检测及制备方法 |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| CN111603567B (zh) * | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| CN113702632A (zh) * | 2021-09-02 | 2021-11-26 | 深圳市光与生物科技有限公司 | 一种快速检测子痫前期的免疫层析检测卡及其制备方法与应用 |
| CN114702564A (zh) * | 2021-12-15 | 2022-07-05 | 江苏省人民医院（南京医科大学第一附属医院） | 一种外泌体肽及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3194732A (en) | 1960-10-03 | 1965-07-13 | Neuhauser Irene | Assisting healing of skin-denuded areas on the body with dried non-fibrous egg-shellmembrane products and compositions therefor |
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| AU7757581A (en) | 1980-11-19 | 1982-05-27 | United Energy Technologies Inc. | Enhanced surface tubing |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| US4630115A (en) | 1983-05-09 | 1986-12-16 | The General Electric Company, P.L.C. | Cathode ray tube display device |
| US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| JP3065628B2 (ja) * | 1988-12-19 | 2000-07-17 | 三井化学株式会社 | ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法 |
| US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| AU648140B2 (en) | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
| IL99120A0 (en) * | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| JP3589665B2 (ja) | 1992-10-23 | 2004-11-17 | イミュネックス・コーポレーション | 可溶性オリゴマー蛋白質の調製法 |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| CZ343795A3 (en) * | 1993-06-29 | 1996-07-17 | Chiron Corp | Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity |
| DK1486565T3 (da) * | 1995-10-11 | 2008-03-10 | Novartis Vaccines & Diagnostic | Kombination af PDGF, KGF, IGF og IGFBP til sårheling |
| CA2288351A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
| US6583168B1 (en) | 1997-11-25 | 2003-06-24 | Applera Corporation | Sulfonated diarylrhodamine dyes |
| US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| CA2331382A1 (en) | 1998-06-18 | 1999-12-23 | Curagen Corporation | Interaction of p27(kip1) with fkbp-12 |
| CN1281465A (zh) * | 1998-10-09 | 2001-01-24 | 上海第二医科大学 | 人fk506结合蛋白(fkbp) |
| JP4821031B2 (ja) | 1999-04-13 | 2011-11-24 | 株式会社林原生物化学研究所 | シアニン色素 |
| AU771904B2 (en) * | 1999-06-22 | 2004-04-08 | Research Development Foundation | Enhanced wound coverage to enhance wound healing |
| AU6074000A (en) * | 1999-07-06 | 2001-01-22 | Incyte Genomics, Inc. | Human immune response molecules |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US20030125246A9 (en) * | 2000-01-31 | 2003-07-03 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| EP1356108A2 (en) * | 2000-11-28 | 2003-10-29 | Wyeth | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| PL215170B1 (pl) * | 2001-06-22 | 2013-10-31 | Hoffmann La Roche | Sposób wytwarzania rozpuszczalnego kompleksu zawierajacego amyloidogenne bialko docelowe oraz bialko opiekuncze z klasy izomeraz peptydyloprolilowych |
| US6856185B2 (en) * | 2001-10-23 | 2005-02-15 | Arris International, Inc. | Simple RMS to DC converter |
| US20040053388A1 (en) * | 2002-01-03 | 2004-03-18 | Eckert Jorg H. | Detection of protein conformation using a split ubiquitin reporter system |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| WO2006138275A2 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2006
- 2006-06-09 GB GBGB0611405.2A patent/GB0611405D0/en not_active Ceased
-
2007
- 2007-06-08 AU AU2007255196A patent/AU2007255196B2/en not_active Ceased
- 2007-06-08 US US12/303,343 patent/US9381228B2/en not_active Expired - Fee Related
- 2007-06-08 JP JP2009513764A patent/JP5474535B2/ja not_active Expired - Fee Related
- 2007-06-08 DK DK07733118.9T patent/DK2040728T3/en active
- 2007-06-08 CN CN2007800276683A patent/CN101489575B/zh not_active Expired - Fee Related
- 2007-06-08 CA CA2657947A patent/CA2657947C/en not_active Expired - Fee Related
- 2007-06-08 ES ES07733118.9T patent/ES2548332T3/es active Active
- 2007-06-08 WO PCT/GB2007/002107 patent/WO2007141533A2/en not_active Ceased
- 2007-06-08 PT PT77331189T patent/PT2040728E/pt unknown
- 2007-06-08 PL PL07733118T patent/PL2040728T3/pl unknown
- 2007-06-08 EP EP07733118.9A patent/EP2040728B1/en not_active Not-in-force
- 2007-06-08 NZ NZ600690A patent/NZ600690A/en not_active IP Right Cessation
- 2007-06-08 NZ NZ573425A patent/NZ573425A/en not_active IP Right Cessation
- 2007-06-08 HU HUE07733118A patent/HUE028099T2/en unknown
- 2007-06-08 SI SI200731701T patent/SI2040728T1/sl unknown
-
2008
- 2008-11-27 IL IL195580A patent/IL195580A/en not_active IP Right Cessation
- 2008-12-04 ZA ZA2008/10323A patent/ZA200810323B/en unknown
-
2015
- 2015-11-26 CY CY20151101070T patent/CY1116970T1/el unknown
-
2016
- 2016-05-31 US US15/169,452 patent/US20160340401A1/en not_active Abandoned
- 2016-05-31 US US15/169,460 patent/US10577406B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539367A5 (enExample) | ||
| CN108350454B (zh) | 等位基因选择性基因编辑及其用途 | |
| JP2007511216A5 (enExample) | ||
| JP2019519219A5 (enExample) | ||
| JP2019519218A5 (enExample) | ||
| JP2010540453A5 (enExample) | ||
| JP2008056679A5 (enExample) | ||
| JP2013027391A5 (enExample) | ||
| JP2018523668A5 (enExample) | ||
| JP2015513897A5 (enExample) | ||
| JP2010525805A5 (enExample) | ||
| JP2010259439A5 (enExample) | ||
| JP2020510426A5 (enExample) | ||
| WO2019196887A1 (zh) | 一种新型小激活rna | |
| WO2010049777A1 (en) | An expression vector and processes thereof | |
| JP2013504603A5 (enExample) | ||
| JP2008514224A5 (enExample) | ||
| JP2013530965A5 (enExample) | ||
| JP2017525357A5 (enExample) | ||
| WO2020032153A1 (ja) | Ｈｓｐａ８遺伝子のプロモーター | |
| Eghtedari et al. | Neuropilin-1 binding peptide as fusion to diphtheria toxin induces apoptosis in non-small cell lung cancer cell line | |
| Wang et al. | Exploring the Potential and Advancements of Circular RNA Therapeutics | |
| CN101590243A (zh) | 微小rna在制备治疗和/或预防淋巴瘤药物中的应用 | |
| JPWO2020118115A5 (enExample) | ||
| CN1429846A (zh) | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |